Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of Targets of Clinical FOXA1 Mutants Involved in EMT and Immune Suppression in Prostate Cancer

ABSTRACT: FOXA1 is a critical transcription factor in prostate cancer (PCa) progression, functioning as a pioneer factor for the androgen receptor (AR). Its expression is elevated in advanced stages of PCa and plays a central role in oncogenic reprogramming. Recurrent coding mutations in the forkhead DNA-binding domain (FKHD) of FOXA1 become increasingly prevalent in drug-resistant metastatic PCa, particularly clustering in the Wing2 region of FKHD. While recent studies demonstrated that these mutations promote PCa progression, the downstream targets of FKHD mutants remain poorly understood. In this study, we employed three analytical approaches to elucidate these targets: (i) traditional transcriptomic analyses, (ii) chromatin structure–based super-enhancer (SE) profiling, and (iii) immune deconvolution. We identified HPSE, an enzyme that degrades heparan sulfate, as a druggable target activated by FKHD mutants both in vitro and in vivo. SE profiling further revealed that FKHD mutants can reprogram the SE landscape, with FOXP1 emerging as a consistently SE-driven and upregulated gene across multiple FOXA1 mutants. Additionally, FOXA1 mutations were associated with immune suppression in PCa patient samples, and B2M, a key gene in antigen processing and presentation, was notably downregulated in FKHD-mutant tumors. Together, our findings provide new insights into how FOXA1 FKHD mutations drive PCa progression and highlight potential therapeutic targets in tumors harboring these mutations.

ORGANISM(S): Homo sapiens

PROVIDER: GSE306036 | GEO | 2026/06/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

H3K27ac ChIP-seq in LNCaP cell line overexpressing WT or mutant FOXA1

Project description:Our data suggested that FKHD-MSs impair the chromatin binding of FOXA1 to AR-dependent enhancers and thus suppress AR transcriptional activity, and promote PCa progression through increasing FOXA1 binding to a subset of AR-independent enhancers that regulates transcription of genes mediating EMT and metastasis

2019-10-15 | GSE133387 | GEO

FOXA1 ChIP-seq in LNCaP cell line overexpressing WT or mutant FOXA1

2019-10-15 | GSE133386 | GEO

RNA-seq in LNCaP cell line overexpressing WT or mutant FOXA1

2019-10-15 | GSE133384 | GEO

Altered chromatin remodeling by FOXA1 mutations promotes androgen independence and prostate cancer aggressiveness [ChIP-seq]

Project description:FKHD-mutant (FKHDm) FOXA1 has impaired ability to bind chromatin and thus failed to rescue wildtype FOXA1-mediated transcriptional program. FKHDm FOXA1 formed much stronger interaction with the AR protein, thereby preventing AR from binding to the chromatin.

2019-11-21 | GSE128883 | GEO

Altered chromatin remodeling by FOXA1 mutations promotes androgen independence and prostate cancer aggressiveness [gene expression]

2019-11-21 | GSE128882 | GEO

SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1 [ChIP-seq]

Project description:We recently reported that in prostate cancer LSD1 can demethylate the lysine 270 of FOXA1 to stabilize FOXA1 chromatin binding and thus can enhance the activities of AR and other transcription factors that require FOXA1 as a pioneer factor. However, the methyltransferase that can methylate FOXA1 and negatively regulate the LSD1-FOXA1 oncogenic axis remains unknown. SETD7 is initially identified as a transcriptional activator through methylating histone 3 lysine 4 but can also function as a methyltransferase on other non-histone substrates. However, its function in PCa remains poorly understood. In this study, we found that SETD7 confers tumor suppressor activity in PCa cells and that loss of SETD7 expression is significantly associated with PCa progression and tumor aggressiveness. Mechanistically, we found that SETD7 primarily acts as a transcriptional repressor in CRPC cells by functioning as a methyltransferase of FOXA1-K270 to disrupt FOXA1-mediated transcription. Overall, our study provides novel mechanistic insights into the tumor-suppressive and transcriptional repression activities of SETD7 in mediating PCa progression and therapy resistance.

2023-08-23 | GSE218092 | GEO

AR RIME in Human Prostate Cancer Cells

Project description:BPTF, the scaffolding subunit of the nucleosome remodeling factor (NURF) complex, has been implicated in the progression of several malignancies, but its role in prostate cancer (PCa) remains unclear. Here, we demonstrate that BPTF is upregulated in castration-resistant prostate cancer (CRPC) and promotes disease progression. RNA-seq revealed that BPTF primarily enhances the expression of androgen receptor (AR) target genes. ChIP-seq showed that BPTF increases AR binding at promoters, enhancers and super-enhancers. ATAC-seq further demonstrated that BPTF increases chromatin accessibility to facilitate AR binding, in part through SMARCA1, a catalytic subunit of the NURF complex. Notably, BPTF/AR co-bound regions are highly enriched for FOXA1 motifs but only weakly enriched for AR motifs. We further show that BPTF forms a protein complex with AR and FOXA1, in which FOXA1 recruits the BPTF-AR complex to chromatin, while BPTF stabilizes the AR-FOXA1 interaction. Importantly, BPTF interacts with AR through its bromodomain, and a BPTF bromodomain inhibitor disrupts this interaction, impairs AR signaling and suppresses PCa cell growth. In summary, our findings establish BPTF as a critical regulator of AR activity by promoting chromatin accessibility and stabilizing the AR-FOXA1 complex, highlighting BPTF as a potential therapeutic target in prostate cancer.

2025-11-19 | PXD070903 | Pride

Genomic analyses of primary mouse prostate organoid culture with overexpression of FOXA1

Project description:Mutations in the FOXA1 transcription factor define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is unknown. By annotating the FOXA1 mutation landscape from 3086 human prostate cancers, we define two hotspots in the forkhead domain: Wing2 (~50% of all mutations) and R219 (~5%), a highly conserved DNA contact residue. Clinically, Wing2 mutations are seen in adenocarcinomas at all stages, whereas R219 mutations are enriched in metastatic tumors with neuroendocrine histology. Interrogation of the biologic properties of FOXA1WT and 14 FOXA1 mutants revealed gain-of-function in mouse prostate organoid proliferation assays. ATAC-seq of FOXA1WT and representative Wing2 and R219 mutants revealed dramatic, mutant-specific changes in open chromatin at thousands of genomic loci, together with novel sites of FOXA1 binding and associated increases in gene expression. Of note, peaks in R219 mutant expressing cells lack the canonical core FOXA1 binding motifs (GTAAAC/T) but are enriched for a related motif (GTAAAG/A), which is preferentially activated by R219 mutant FOXA1 in reporter assays. Thus, FOXA1 mutations alter its normal pioneering function and promote oncogenesis through perturbation of normal luminal epithelial differentiation programs, providing further support to the role of lineage plasticity in cancer progression.

2019-06-21 | GSE128867 | GEO

FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment

Project description:Forkhead box A1 (FOXA1) is a lineage-specifying transcription factor that is often de-regulated prostate cancer (PCa), with previous studies reporting both tumor-promoting and -inhibitory functions. Little is known about FOXA1 function in a physiological setting of PCa progression. Here we report that Foxa1 knockout in the Pten-null prostate epithelium in vivo leads to an aggressive sub-type of PCa marked by basal/squamous de-differentiation, tissue disorganization, and poor survival. Single-cell RNA-seq revealed a major increase of basal/squamous gene expression in the epithelium, which was accompanied by inflammatory and immunosuppressive cytokine signaling. Mechanistically, in addition to its well-known role in inducing luminal genes, FOXA1 directly inhibits many basal/squamous and inflammatory genes, which are unleashed upon Foxa1 knockout. Significantly, there is a striking remodeling of the tumor immune microenvironment in Foxa1-depleted PCa, with increased tumor infiltration by immunosuppressive myeloid populations and dysfunctional and spatially confined T cells. These important findings were further confirmed in human PCa samples via single-cell and spatial transcriptomic analyses. Altogether, we report critical roles for FOXA1 loss in inducing basal/squamous de-differentiation and an immunosuppressive microenvironment.

2026-02-21 | GSE282721 | GEO

FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function

Project description:FOXA1 is a FKHD family protein that translates epigenetic signatures at target enhancers to lineage-specific transcription and differentiation. Through genome-wide location analyses, here we show that FOXA1 expression and occupancy are, in turn, required for the maintenance of this epigenetic signature, namely DNA hypomethylation and histone 3 lysine 4 methylation. Mechanistically, this involves TET1, a 5-methylcytosine dioxygenase. We found that FOXA1 induces TET1 expression via direct binding at its cis-regulatory elements. Further, FOXA1 physically interacts with the TET1 protein through its CXXC domain. TET1 thus co-occupies FOXA1-dependent enhancers and mediates local DNA demethylation and concomitant histone 3 lysine 4 methylation, further potentiating FOXA1 recruitment. FOXA1 binding events were markedly reduced following TET1 depletion. Together, our results support that FOXA1 is not only a reader, but also a writer, of the epigenetic signatures at lineage-specific enhancers and that TET1 and FOXA1 form a feed-forward regulatory loop for enhancer activation. ChIP-Seq examination of FOXA1 binding sites in LNCaP cell, and epigenetic markers (5mC, 5hmC, H3K4me2) profiling upon TET1 depletion

2016-07-22 | E-GEOD-73363 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data